[WCN21;206_Q&A]

Multiple Sclerosis & Demyelinating Disorders

Moderator: Xavier Montalban

Emanuele D'amico
Exit-Strategies in Natalizumab Responders Rrms Patients: An Italian Comparison Among Ocrelizumab, Retuximab and Cladribine

Maria Rocca
The Role of Brain Network Functional Connectivity and Machine Learning For The Classification and Characterization of Disease Phenotypes in Patients With Multiple Sclerosis

Emilio Portaccio
Progression Independent of Relapse Activity in Early Multiple Sclerosis Patients

Lorenzo Gaetani
A CSF Biomarker of Intrathecal B Cells Activation Correlates With Memory Impairment in Multiple Sclerosis

Claudia Cutelle'
Immunoglobulin Free Light Chains As a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Real Life Study.

Aurora Zanghì
Disease-Modifying Therapies in Non-Relapsing Multiple Sclerosis Do Not Influence Risk of Requiring a Wheelchair After Secondary Progression

Alessia Sarica
Microstructural Alterations of The Spinothalamic Tract and Neuropathic Pain: A Diffusion Tensor Imaging Study in Relapsing Remitting Multiple Sclerosis

Luca Prosperini
Increased Risk of Death From Covid-19 in Multiple Sclerosis: A Meta-Analysis of Observational Studies